Supply increased to 10 million doses! Danish monkeypox vaccine manufacturer plans to expand production capacity
2024-08-19
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
(CCTV Finance "World Finance")Currently, only a few companies in the world have been approved to produce monkeypox vaccines. According to Reuters, one of the manufacturers, Danish pharmaceutical company Bavaria Nordic Biotech, said on August 17 that it plans to increase its monkeypox vaccine production capacity and expand the scope of vaccination.
Bavaria's Nordic Biotech said it has supplied up to 2 million doses of monkeypox vaccine so far this year and plans to increase supply to 10 million doses by the end of 2025. The company also said it is expanding its production network to Africa and is ready to work with the Africa Centers for Disease Control and Prevention and the World Health Organization to make the vaccine available to all countries.
The monkeypox vaccine mentioned by Bavaria Nordic Biotech was originally developed to prevent infection with the smallpox virus. The World Health Organization previously estimated that the vaccine is 85% effective in preventing monkeypox virus. This is also the only monkeypox vaccine approved by the US Food and Drug Administration and the European Medicines Agency, and is currently only approved for adults aged 18 and above. The company announced on its official website on the 16th that it has submitted clinical data to the European Medicines Agency, seeking to expand the vaccine's indications to adolescents aged 12 to 17.
Please indicate CCTV Finance when reprinting
Editor: Anqi
